For consideration of USD 3 mnSun Pharmaceuticals Industries announced that one of the wholly owned subsidiaries of the company has agreed to acquire shares of Tarsius Pharma, ('Tarsius'), Israel, by way of subscription of 345,622 ordinary shares of nominal value of NIS 0.01 each, representing 18.75% of shares of Tarsius, on a fully diluted basis.
The cost of acquisition is USD 3 million.
Tarsius is an Israel based early stage research and development company focusing on development of drug candidates in the field of Ophthalmology.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)